Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
30.75
+0.83 (2.77%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Tectonic Therapeutic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
60
Market Cap
601.14M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 316.70M |
| REGENXBIO | 174.48M |
| Autolus Therapeutics | 117.39M |
| ARS Pharmaceuticals | 116.93M |
| Scribe Therapeutics | 36.28M |
| ProKidney | 818.00K |
| Altimmune | 31.00K |
TECX News
- 3 days ago - Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - Tectonic Therapeutic Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Tectonic Therapeutic Earnings release: Q2 2026 - Filings
- 5 weeks ago - Tectonic Therapeutic Slides: Investor presentation - Filings
- 2 months ago - Tectonic Therapeutic completes enrollment for APEX trial - TheFly
- 2 months ago - Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients - GlobeNewsWire
- 3 months ago - Tectonic Therapeutic Transcript: AGM 2026 - Transcripts